It has been shown that inhibition of NF-κB results in anti-glioma activity, and also reduces TMZ-induced chemoresistance via down-regulation of O6-methylguanine-DNA methyltransferase (MGMT) gene expression[61]. This evidence concerns the gene NFKB1 and glioma.